Relieves osteoarthritis and rheumatoid arthritis. ANDA 78671, held by Invagen Pharms. Nabumetone.
As of Nov 15, 2026, ANDA 78671 (Nabumetone), held by Invagen Pharms, was first approved by FDA on Mar 7, 2008, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets, USP and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets, USP are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 7, 2008 | Original application | Approved | None posted |
| Nabumetone500MG · tablet;oral | Nabumetone | Rx |
| Nabumetone750MG · tablet;oral | Nabumetone | Rx |
| Nov 21, 2024 | Supplement 24Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 20Labeling · Standard review | Approved | None posted |
| May 9, 2016 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 7, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters